Immunogenicity considerations for antibody–drug conjugates: a focus on neutralizing antibody assays

References

• 1 Schwartz RS. Paul Ehrlich's magic bullets. N. Engl. J. Med. 350, 1079–1080 (2004).
  Medline CASGoogle Scholar
• 2 Sievers EL, Senter PD. Antibody–drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15–29 (2013).
  Medline CASGoogle Scholar
• 3 Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 76(2), 248–262 (2013).
  Medline CASGoogle Scholar
• 4 Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16(2), 209 (2014).
  MedlineGoogle Scholar
• 5 Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346(7), 469–475 (2002).
  Medline CASGoogle Scholar
• 6 US FDA. Guidance for Industry. Immunogenicity Assessment for Therapeutic Protein Products. Washington, DC, USA (2014). www.fda.gov/downloads/drugs/guidances/ucm338856.pdf.
  Google Scholar
• 7 US FDA. Draft Guideline. Guidance for Industry. Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Product. Washington, DC, USA (2016). www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf.
  Google Scholar
• 8 Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency, London, UK (2015). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf.
  Google Scholar
• 9 Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1–2), 1–9 (2008).
  Medline CASGoogle Scholar
• 10 Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555–561 (2007).
  Medline CASGoogle Scholar
• 11 Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell. Immunol. 295, 118–126 (2015).
  Medline CASGoogle Scholar
• 12 Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug. Chem. 19(1), 358–361 (2008).
  Medline CASGoogle Scholar
• 13 de Goeij B, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr. Opin. Immunol. 40, 14–23 (2016).
  Medline CASGoogle Scholar
• 14 Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake. Cancer Immunol. Immunother. 62(2), 217–223 (2013).
  Medline CASGoogle Scholar
• 15 Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 149(3), 534–555 (2013).
  Medline CASGoogle Scholar
• 16 Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17(1), 35–43 (2015).
  Medline CASGoogle Scholar
• 17 Carrasco-Triguero M. Insights on the immunogenicity of antibody–drug conjugates. Bioanalysis 7(13), 1565–1568 (2015).
  CASGoogle Scholar
• 18 Kadcyla (ado-trastuzumab emtansine) [prescribing information]. Genentech Inc., CA, USA (2016). www.gene.com/download/pdf/kadcyla_prescribing.pdf.
  Google Scholar
• 19 Adcetris (brentuximab vedotin) [prescribing information]. Seattle Genetics, Inc., WA, USA (2016). www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf.
  Google Scholar
• 20 Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: Adcetris. Office of Clinical Pharmacology, MD, USA (2011). www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ClinPharmR.pdf.
  Google Scholar
• 21 Wyeth-Ayerst. Gemtuzumab ozogamicin, summary for presentation to the FDA's Oncologic Division Advisory Committee (2000). www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b2c.pdf.
  Google Scholar
• 22 Shankar G, Devanaryan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267–1281 (2008).
  Medline CASGoogle Scholar
• 23 Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1–16 (2004).
  Medline CASGoogle Scholar
• 24 Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods 408, 1–12 (2014).
  Medline CASGoogle Scholar
• 25 Hoofring SA, Lopez R, Hock MB et al. Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates. Bioanalysis 5(9), 1041–1055 (2013).
  CASGoogle Scholar
• 26 Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell based assays used for detection of neutralizing antibody responses elicited to biological therapeutics. J. Pharm. Biomed. Anal. 55(5), 878–888 (2011).
  Medline CASGoogle Scholar
• 27 Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321, 1–18 (2007).
  Medline CASGoogle Scholar
• 28 Finco D, Baltrukonis D, Clements-Egan A et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Anal. 54(2), 251–358 (2011).
  Google Scholar
• 29 Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9(10), 790–803 (2010).
  Medline CASGoogle Scholar
• 30 Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol. Rev. 68, 3–19 (2016).
  Medline CASGoogle Scholar
• 31 Oflazoglu E, Stone IJ, Gordon KA et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110(13), 4370–4372 (2007).
  Medline CASGoogle Scholar
• 32 Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128(2), 347–356 (2011).
  Medline CASGoogle Scholar
• 33 Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In vivo Clinical Use. European Medicines Agency, London, UK (2012). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
  Google Scholar
• 34 Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis 4(24), 2959–2970 (2012).
  CASGoogle Scholar
• 35 Wu B, Chung S, Jiang XR et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 18(6), 1335–1350 (2016).
  Medline CASGoogle Scholar
• 36 Loebrich S, Shen M, Cohen E et al. Development and characterization of a neutralizing anti-idiotype antibody against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 19(4), 1223–1234 (2017).
  Medline CASGoogle Scholar
• 37 Li W, Lam MS, Birkeland A. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Parmacol. Toxicol. Meth. 54, 313–319 (2006).
  Medline CASGoogle Scholar
• 38 Barbosa MD, Gleason CR, Phillips KR et al. Addressing drug effects on cut point determination for an anti-drug antibody assay. J. Immunol. Methods 284(1–2), 152–156 (2012).
  Google Scholar
• 39 Chatterjee S, Vashishta L, Waichale VS et al. Development and validation of a cell based assay for the detection of neutralizing antibodies against recombinant insulins. J. Immunol. Methods 1759(17), 30153–30159 (2017).
  Google Scholar
• 40 Ray CA, Patel V, Shih J et al. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. J. Pharm. Biomed. Anal. 49(2), 311–318 (2009).
  Medline CASGoogle Scholar
• 41 Chen XC, Zhou L, Gupta S, Civoli F. Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. J. Immunol. Methods 376(1–2), 32–45 (2012).
  Medline CASGoogle Scholar
• 42 Gorovits B, Clements-Egan A, Birchler M et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 18(2), 311–330 (2016).
  Medline CASGoogle Scholar
• 43 O'Hara DM, Theobald V, Egan AC et al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 14(2), 316–328 (2012).
  MedlineGoogle Scholar
• 44 Geist BJ, Egan AC, Yang TY, Dong Y, Shankar G. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. Bioanalysis 5(2), 227–244 (2013).
  CASGoogle Scholar